New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After VaccinationGlobeNewsWire • 12/15/21
Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal DegenerationGlobeNewsWire • 12/09/21
Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in NovemberThe Motley Fool • 12/04/21
Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)GlobeNewsWire • 11/26/21
Ocugen-Partnered Bharat Biotech's COVID-19 Shot Shows 50% Effectiveness In Small Study In IndiaBenzinga • 11/24/21